Blog
Something inspiring would go here to explain the blog.
-
Medtech Canada advocates for “zero for-zero” tariffs to safeguard affordability and supply of medical technologies in Canadian health care
By
Why This Matters: Tariffs on medical technologies can drive up healthcare costs, limit the availability of essential equipment, and delay care for patients who need timely treatment. Keeping these products […]
-
‘An urgent public health crisis:’ Why so many people are struggling to get medicine
By
Why This Matters: When global supply chains falter, Canadian patients can face drug delays or cost increases. A resilient system means better access, less disruption, and fewer surprises in care. […]
-
Think Tank Calls on Ottawa to Abandon Single-payer Pharmacare Model
By
Why This Matters: A pharmacare model that removes existing coverage could leave many Canadians without the medicines they currently rely on. Canadians deserve a system that expands access, not one […]
-
Waiting for New Medicines in Canada, Europe, and the United States
By
In this article by the Canadian Health Policy Institute, readers learn that Canadians wait far longer than patients in the U.S. or Europe to access newly approved medicines. Submission delays, […]
-
Health Canada to Modernize Biologic Drug Submission
By
In this article by Torys LLP, they explain an announcement from Health Canada that makes it easier and faster for new biologic and biosimilar medicines to be approved. The updated […]
-
Health and Life Sciences M&A in the Waiting Room as Tariff and Economic Uncertainty Grow
By
In this article by Zena Olijnyk for Lexpert, readers see how U.S. tariff threats and economic uncertainty are putting Canadian health and life sciences dealmaking on hold. Buyers and sellers […]
-
Pharmaceutical Industry Urges G7 to Prioritize Health Innovation as Global Strategic Pillar
By
In this article by IFPMA and Innovative Medicines Canada, they called on leaders to make health innovation a cornerstone of G7 policy. The open letter asked leaders to invest in […]
-
Let’s Fix What’s Broken, without Breaking What’s Working
By
In this article by Dr. Bettina Hamelin of Innovative Medicines Canada, readers learn about the risks of replacing private drug plans with a limited national formulary and how that could […]
-
Trump Wants to Tariff Canadian-made Drugs
By
In this article from CBC News, they explain how proposed U.S. tariffs on Canadian-made medicines could disrupt cross-border supply chains, increase costs, and risk shortages of essential drugs. Experts warn […]
-
Patient Choice a Top Priority: Why Pharmacare Must Put Canadians First
By
Canada’s proposed pharmacare plan risks limiting patient choice by replacing effective, personalized treatments with a narrow one-size-fits-all formulary. Innovative Medicines Canada warns this could harm those with chronic or complex […]